Capmatinib in Treating Patients with Recurrent or Advanced Non-small Cell Lung Cancer with MET Exon 14 Alterations or MET Amplification Previously Treated with MET Inhibitor Therapy

Status: Active


This phase II trial studies how well capmatinib works in treating patients with non-small cell lung cancer with MET exon 14 alterations or MET amplification that has previously been treated with MET inhibitor therapy and has come back or spread to other places in the body. Capmatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

Inclusion Criteria

  • Written informed consent must be obtained prior to any screening procedures
  • Histologically or cytologically confirmed non-small cell lung cancer, advanced, recurrent, or metastatic
  • MET exon 14 skipping alteration or MET amplification (MET:CEP7 ratio >= 1.8) by molecular testing (local testing is accepted for eligibility; all patients will have confirmation at Massachusetts General Hospital [MGH] but this result is not necessary for eligibility; local molecular pathology result will suffice); this testing can be from any archival or fresh sample
  • Must have received prior platinum containing chemotherapy for advanced/metastatic non-small cell lung cancer, or have refused or be ineligible for such therapy; prior neoadjuvant/adjuvant platinum containing chemotherapy will count has having received prior platinum, provided that disease recurred within 6 months of completion of neoadjuvant/adjuvant therapy
  • EGFR and ALK status must be known in all patients with adenocarcinoma histology; patients with activating EGFR mutations or ALK translocations are excluded from this study, unless disease has progressed on all available, approved therapies targeting these alterations
  • At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation
  • Must have received prior therapy with a MET inhibitor; patients must have recovered from all toxicities related to prior anticancer therapies to grade =< 1 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0); patients with any grade of alopecia are allowed to enter the study
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support (at the screening visit)
  • Platelets >= 75 x 10^9/L (at the screening visit)
  • Hemoglobin (Hgb) > 9 g/dL (at the screening visit)
  • Calculated creatinine clearance (using Cockcroft-Gault formula) > 45 mL/min (at the screening visit)
  • Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with Gilbert’s syndrome, who may only be included if total bilirubin =< 3.0 x ULN or direct bilirubin =< 1.5 x ULN (at the screening visit)
  • Aspartate transaminase (AST) =< 3 x ULN, except for patients with liver metastasis, who are included if AST =< 5 x ULN (at the screening visit)
  • Alanine transaminase (ALT) =< 3 x ULN, except for patients with liver metastasis, who are only included if ALT =< 5 x ULN (at the screening visit)
  • Alkaline phosphatase (ALP) =< 5.0 x ULN (at the screening visit)
  • Asymptomatic serum amylase =< grade 2 and asymptomatic serum lipase =< grade 2; patients with grade 1 or grade 2 serum amylase or lipase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.) (at the screening visit)
  • Patients must have the following laboratory values within the laboratory normal limits or corrected to within normal limits with supplements during screening: * Potassium * Magnesium * Phosphorus * Total calcium (corrected for serum albumin)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  • Willing and able to comply with scheduled visits, treatment plan and laboratory tests

Exclusion Criteria

  • Patients with known hypersensitivity to any of the excipients of INC280 (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes)
  • Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms
  • Presence or history of a malignant disease other than disease to be treated in current protocol that has been diagnosed and/or required therapy within the past 3 years; exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resected carcinoma in situ of any type
  • Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis
  • Clinically significant, uncontrolled heart diseases * Unstable angina within 6 months prior to screening * Myocardial infarction within 6 months prior to screening * History of documented congestive heart failure (New York Heart Association functional classification III-IV) * Uncontrolled hypertension defined by a systolic blood pressure (SBP) >= 160 mm Hg and/or diastolic blood pressure (DBP) >= 100 mm Hg, with or without antihypertensive medication; initiation or adjustment of antihypertensive medication (s) is allowed prior to screening * Ventricular arrhythmias * Supraventricular and nodal arrhythmias not controlled with medication * Other cardiac arrhythmia not controlled with medication * Fridericia's correction formula (QTcF) > 480 msec
  • Thoracic radiotherapy to lung fields =< 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities; for all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy =< 2 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities; palliative radiotherapy for bone lesions =< 2 weeks prior to starting INC280 is allowed
  • Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting INC280 or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
  • Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with INC280 and for the duration of the study: * Strong and moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) * Strong inducers of CYP3A4 * Proton pump inhibitors (PPI)
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of INC280 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)
  • Unable or unwilling to swallow tablets as per dosing schedule
  • Patients receiving unstable or increasing doses of corticosteroids; if patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized (or decreasing) for at least 5 days before first dose of INC280
  • Patients receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of INC280, and for the duration of the study; patients on non-enzyme-inducing anticonvulsants are eligible
  • Previous anti-cancer and investigational agents within 2 weeks before first dose of INC280; if previous treatment is a small molecule tyrosine kinase inhibitor (TKI), last dose must be at least 7 days before first dose of INC280; a shorter washout period may be allowed after discussion with the principal investigator
  • Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities that in the opinion of the investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results
  • Any other condition that would, in the investigator’s judgment, contraindicate patient’s participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.
  • Pregnant or nursing women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 30 days after stopping treatment; highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment * Male sterilization (at least 6 months prior to screening); for female subjects on the study the vasectomized male partner should be the sole partner for that subject * Combination of any two of the following: ** Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate =< 1%), for example hormone vaginal ring or transdermal hormone contraception ** Placement of an intrauterine device (IUD) or intrauterine system (IUS) ** Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository * In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
  • Sexually active males unless they use a condom during intercourse while taking drug and for 7 days after stopping treatment and should not father a child in this period; a condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid; for males with female partners of childbearing potential, couples must use highly effective means of contraception while taking the study drug

Locations & Contacts


Beth Israel Deaconess Medical Center
Status: Active
Contact: Daniel Botelho Costa
Phone: 617-667-9236
Massachusetts General Hospital Cancer Center
Status: Active
Contact: Rebecca Suk Heist
Phone: 617-724-4000

Trial Objectives and Outline


I. To assess the objective response rate in patients with lung cancer with MET exon 14 (METex14) or MET amplification with prior exposure to MET inhibitor therapy, when treated with capmatinib (INC280).


I. To assess progression-free survival (PFS), disease control rate (DCR), intracranial response rate (IRR), and duration of response (DOR) in patients with lung cancer with METex14 or MET amplification with prior exposure to MET inhibitor therapy, when treated with INC280.

II. To assess overall survival (OS) in patients with lung cancer with METex14 or MET amplification with prior exposure to MET inhibitor therapy, when treated with INC280.

III. To assess safety and tolerability of INC280 among patients with lung cancer with METex14 or MET amplification treated with INC280.


I. To explore potential biomarkers of response and resistance to INC280.

II. To explore co-occurrence of METex14 with MET amplification, mouse double minute 2 (MDM2) amplification, and cyclin-dependent kinase 4 (CDK4) amplification, among others, and impact on response.

III. To generate patient derived xenograft (PDX) and cell line models to explore the biology underlying sensitivity and resistance.


Patients receive capmatinib orally (PO) twice daily (BID) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment patients are followed up for up to 30 days and then every 3 months for up to 2 years.

Trial Phase & Type

Trial Phase

Phase II

Trial Type


Lead Organization

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Rebecca Suk Heist

Trial IDs

Primary ID 16-019
Secondary IDs NCI-2016-00892 ID NCT02750215